Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Chi-Med's Surufatinib, Generic Ibrance Among Latest China Approvals

Large Batch Of Late 2020 Nods

Jan 14 2021

• By Brian Yang

Form close up, fountain pen and approved stamped on a document. Soft focus. - Image — CHINA CONTINUES NEW DRUG APPROVAL SPURT • Source: Shutterstock

Related Content

China Provides Patent Linkage In Latest Law Draft - Why Now?

Jul 15 2020

Related Companies

HUTCHMED (China) Limited

InnoCare Pharma Ltd.

Jiangsu Hengrui Pharmaceuticals

Qilu Pharmaceutical Co., Ltd.

Pfizer Inc.

Merck & Co., Inc.

GSK plc

Gan & Lee Pharmaceuticals

Novo Nordisk A/S

Novartis AG

Innovent Biologics, Inc.

Eli Lilly and Company

BeOne Medicines Ltd.

Gilead Sciences, Inc.

Roche Holding AG

Additional Topics

China Asia Pacific Approvals Biosimilars Intellectual Property ImmunoOncology Regulation BioPharmaceutical

More from China

More from Asia

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window